13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001856083
Total reported value
$6.9B
$6.9B
62 檔
12.7%
According to the latest 13F quarterly dataset, Deep Track Capital, LP managed an equity portfolio of $6.9B at the end of Q4 2024, spanning 62 distinct U.S. exchange-listed positions.
In Q4 2024, Deep Track Capital, LP adopted a defensive or profit-taking posture, trimming 20 positions and completely liquidating 22 holdings to manage risk exposure.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | DVAX | Dynavax Technologies CORP | Stock-Other | 8.47% | — | +42.03% | |
| 2 | GH | Guardant Health Inc | Stock-Healthcare | 7.31% | +2.37% | +6.98% | |
| 3 | ITCIEUR | Intra-cellular Therapies Inc | Stock-Other | 6.23% | — | +24.95% | |
| 4 | IMVT | Immunovant Inc | Stock-Other | 5.54% | +0.56% | +38.01% | |
| 5 | APLSUSD | Apellis Pharmaceuticals Inc | Stock-Other | 5.09% | -2.98% | EXIT | |
| 6 | SWTXUSD | Springworks Therapeutics Inc | Stock-Other | 4.66% | — | -9.97% | |
| 7 | CYTK | Cytokinetics Inc | Stock-Healthcare | 4.39% | -0.61% | +296.88% | |
| 8 | OCUL | Ocular Therapeutix Inc | Stock-Other | 4.09% | +0.09% | +0.90% | |
| 9 | VRDN | Viridian Therapeutics Inc | Stock-Other | 3.23% | +0.51% | +20.58% | |
| 10 | PLRX | Pliant Therapeutics Inc | Stock-Other | 2.93% | — | — | |
| 11 | GPCR | Structure Therapeutics Inc | Stock-Other | 2.83% | +0.33% | +129.41% | |
| 12 | IONS | Ionis Pharmaceuticals Inc | Stock-Healthcare | 2.52% | +0.15% | -12.09% | |
| 13 | NRIX | Nurix Therapeutics Inc | Stock-Other | 2.11% | +1.12% | -22.44% | |
| 14 | MBX | Mbx Biosciences Inc | Stock-Other | 2.08% | +0.05% | — | |
| 15 | NMRA | Neumora Therapeutics Inc | Stock-Other | 2.05% | — | +593.89% | |
| 16 | ETNBGBP | 89bio Inc | Stock-Other | 1.89% | — | +134.17% | |
| 17 | HRMY | Harmony Biosciences Holdings | Stock-Other | 1.86% | — | — | |
| 18 | DYN | Dyne Therapeutics Inc | Stock-Other | 1.76% | -0.11% | -39.06% | |
| 19 | SEPN | Septerna Inc | Stock-Other | 1.63% | — | — | |
| 20 | GMAB | Genmab A/s -sp Adr | Stock-Other | 1.56% | +1.86% | — | |
| 21 | AKRO | Akero Therapeutics Inc | Stock-Other | 1.55% | — | +116.01% | |
| 22 | VRNA | Verona Pharma PLC - Adr | Stock-Other | 1.47% | — | -73.27% | |
| 23 | CLDX | Celldex Therapeutics Inc | Stock-Other | 1.45% | +0.92% | — | |
| 24 | PTGX | Protagonist Therapeutics Inc | Stock-Other | 1.44% | — | — | |
| 25 | ANIP | Ani Pharmaceuticals Inc | Stock-Other | 1.34% | -0.75% | EXIT | |
| 26 | BCAX | Bicara Therapeutics Inc | Stock-Other | 1.30% | +0.45% | +150.99% | |
| 27 | AUTL | Autolus Therapeutics PLC | Stock-Other | 1.25% | — | -6.90% | |
| 28 | KRRO | Korro Bio Inc | Stock-Other | 1.24% | — | +2.90% | |
| 29 | 430 | Terns Pharmaceuticals Inc | Stock-Other | 1.15% | -0.92% | EXIT | |
| 30 | ✓ | Engene Holdings Inc | Stock-Other | 1.13% | -0.49% | EXIT | |
| 31 | RARE | Ultragenyx Pharmaceutical In | Stock-Other | 1.03% | — | — | |
| 32 | ABVX | Abivax Sa-adr | Stock-Other | 0.98% | — | — | |
| 33 | 260 | Centessa Pharmaceuticals-adr | Stock-Other | 0.84% | -2.05% | EXIT | |
| 34 | BBIO | Bridgebio Pharma Inc | Stock-Healthcare | 0.84% | -1.02% | EXIT | |
| 35 | LKFT | Lakefront Biotherapeutic-adr | Stock-Other | 0.80% | — | — | |
| 36 | OLMA | Olema Pharmaceuticals Inc | Stock-Other | 0.75% | +0.27% | NEW | |
| 37 | BRD1EUR | Mind Medicine Mindmed Inc | Stock-Other | 0.73% | — | -60.13% | |
| 38 | EWTX | Edgewise Therapeutics Inc | Stock-Other | 0.71% | — | -35.45% | |
| 39 | BCYC | Bicycle Therapeutics Plc-adr | Stock-Other | 0.67% | — | -64.03% | |
| 40 | UPB | Upstream Bio Inc | Stock-Other | 0.61% | — | — | |
| 41 | NVAX | Novavax Inc | Stock-Healthcare | 0.60% | — | — | |
| 42 | IMCR | Immunocore Holdings Plc-adr | Stock-Other | 0.57% | -0.81% | — | |
| 43 | ORKA | Oruka Therapeutics Inc | Stock-Other | 0.54% | +1.04% | -39.28% | |
| 44 | GERN | Geron CORP | Stock-Other | 0.53% | -0.77% | EXIT | |
| 45 | HELP | Cybin Inc | Stock-Other | 0.50% | -0.10% | EXIT | |
| 46 | XNCR | Xencor Inc | Stock-Other | 0.43% | +0.14% | NEW | |
| 47 | ALGS | Aligos Therapeutics Inc | Stock-Other | 0.36% | -0.01% | — | |
| 48 | ✓ | Rapt Therapeutics Inc | Stock-Other | 0.35% | — | — | |
| 49 | ✓ | Zura Bio LTD | Stock-Other | 0.31% | — | — | |
| 50 | CNTX | Context Therapeutics Inc | Stock-Other | 0.29% | -0.26% | — |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | DVAX | Dynavax Technologies CORP | +4% | +42.03% | Add |
| 2 | CYTK | Cytokinetics Inc | +3.3% | +296.88% | Add |
| 3 | GH | Guardant Health Inc | +3% | +6.98% | Add |
| 4 | ITCIEUR | Intra-cellular Therapies Inc | +2.5% | +24.95% | Add |
| 5 | HRMY | Harmony Biosciences Holdings | +1.9% | NEW | New buy |
| 6 | NMRA | Neumora Therapeutics Inc | +1.7% | +593.89% | Add |
| 7 | SEPN | Septerna Inc | +1.6% | NEW | New buy |
| 8 | IMVT | Immunovant Inc | +1.6% | +38.01% | Add |
| 9 | GMAB | Genmab A/s -sp Adr | +1.6% | NEW | New buy |
| 10 | CLDX | Celldex Therapeutics Inc | +1.5% | NEW | New buy |
| 11 | PTGX | Protagonist Therapeutics Inc | +1.4% | NEW | New buy |
| 12 | ETNBGBP | 89bio Inc | +1.2% | +134.17% | Add |
| 13 | GPCR | Structure Therapeutics Inc | +1.1% | +129.41% | Add |
| 14 | APLSUSD | Apellis Pharmaceuticals Inc | +1.1% | -2.86% | Trim |
| 15 | RARE | Ultragenyx Pharmaceutical In | +1% | NEW | New buy |
| 16 | AKRO | Akero Therapeutics Inc | +0.9% | +116.01% | Add |
| 17 | BBIO | Bridgebio Pharma Inc | +0.8% | NEW | New buy |
| 18 | PLRX | Pliant Therapeutics Inc | +0.8% | — | Unchanged |
| 19 | LKFT | Lakefront Biotherapeutic-adr | +0.8% | NEW | New buy |
| 20 | SWTXUSD | Springworks Therapeutics Inc | +0.8% | -9.97% | Trim |
| 21 | BCAX | Bicara Therapeutics Inc | +0.7% | +150.99% | Add |
| 22 | UPB | Upstream Bio Inc | +0.6% | NEW | New buy |
| 23 | NVAX | Novavax Inc | +0.6% | NEW | New buy |
| 24 | ✓ | Engene Holdings Inc | +0.6% | +74.78% | Add |
| 25 | OCUL | Ocular Therapeutix Inc | +0.6% | +0.90% | Add |
| 26 | IMCR | Immunocore Holdings Plc-adr | +0.6% | NEW | New buy |
| 27 | VRDN | Viridian Therapeutics Inc | +0.5% | +20.58% | Add |
| 28 | ANIP | Ani Pharmaceuticals Inc | +0.4% | +28.57% | Add |
| 29 | ✓ | Rapt Therapeutics Inc | +0.4% | NEW | New buy |
| 30 | KRRO | Korro Bio Inc | +0.3% | +2.90% | Add |
| 31 | ALGS | Aligos Therapeutics Inc | +0.3% | — | Unchanged |
| 32 | XENE | Xenon Pharmaceuticals Inc | +0.3% | NEW | New buy |
| 33 | OKUR | Onkure Therapeutics Inc-a | +0.2% | NEW | New buy |
| 34 | ALLKGUSD | Allakos Inc | +0.2% | +14.09% | Add |
| 35 | 260 | Centessa Pharmaceuticals-adr | +0.2% | — | Unchanged |
| 36 | HELP | Cybin Inc | +0.1% | — | Unchanged |
| 37 | FLNA | Filana Therapeutics Inc | 0% | NEW | New buy |
| 38 | RGLS | Regulus Therapeutics Inc | 0% | — | Unchanged |
| 39 | SRRK | Scholar Rock Holding CORP | 0% | EXIT | Sold out |
| 40 | MGX | Metagenomi Therapeutics Inc | 0% | EXIT | Sold out |
| 41 | AVTX | Avalo Therapeutics Inc | -0.1% | -10.34% | Trim |
| 42 | SYRS | Syros Pharmaceuticals Inc | -0.1% | EXIT | Sold out |
| 43 | PRTA | Prothena Corporation plc | -0.1% | EXIT | Sold out |
| 44 | RLMD | Relmada Therapeutics Inc | -0.1% | EXIT | Sold out |
| 45 | XNCR | Xencor Inc | -0.1% | -37.50% | Trim |
| 46 | ANRO | Alto Neuroscience Inc | -0.1% | EXIT | Sold out |
| 47 | ✓ | Zura Bio LTD | -0.1% | — | Unchanged |
| 48 | INO | Inovio Pharmaceuticals Inc | -0.1% | +72.87% | Add |
| 49 | CNTX | Context Therapeutics Inc | -0.2% | — | Unchanged |
| 50 | IVVD | Invivyd Inc | -0.2% | -2.41% | Trim |
According to official SEC Form 13F filings, Deep Track Capital, LP reported a total U.S. public equity portfolio value of $6.9B across 62 disclosed positions in Q4 2024.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including DVAX, GH, ITCIEUR) accounted for 12.7% of total reported equity market value during Q4 2024.
Top New Position Initiated
HRMY
市值: $49.9M
Top Position Liquidated / Trimmed
ARGX
前期市值: $197.9M
During Q4 2024, Deep Track Capital, LP's top holdings by market value included DVAX (8.5%)、GH (7.3%)、ITCIEUR (6.2%). The largest single position, DVAX, represented 8.5% of total portfolio value.
In Q4 2024, Deep Track Capital, LP made 74 total portfolio adjustments, initiating 15 new buys, adding to 17 positions, trimming 20 holdings, and fully liquidating 22 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.